Kinvard Bio
Company Details
Status: Private
Employees: 1-10
Location:
Raleigh, North Carolina, United States
Type:
sample
Technology:
sample
About: Kinvard Bio is committed to developing a durable new class of antibiotics to treat the most challenging acute and chronic drug-resistant bacterial infections.
Our chemistry platform technology is based on groundbreaking research that has been exclusively licensed from the Myers lab in the Department of Chemistry and Chemical Biology at Harvard University and funded by the Kineticos AMR Accelerator Fund I (KAMRA I).
The oxepanoprolinamides (OPPs) represent a distinct class of lincosamide antibiotics that are pre-organized for highly effective and differentiated binding to the bacterial ribosome. In preclinical studies, OPPs have proven effective against both Gram-positive and Gram-negative bacterial pathogens associated with clinical needs that remain unmet.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Kinvard Bio | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.